Drugs · acquisition-cost intelligence
Arixtra
fondaparinux sodium· ingredient fondaparinuxOther antithrombotic agents· FONDAPARINUX SODIUM 10 mg/.8mL; FONDAPARINUX SODIUM 2.5 mg/.5mL; FONDAPARINUX SODIUM 5 mg/.4mL; FONDAPARINUX SODIUM 7.5 mg/.6mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$43.37
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 9 weeks.
2025-01-222026-05-20
Medicare Part D coverage · CY2026
On 272 plan formularies · typical tier 5
Prior auth 0% · Step therapy 0% · Quantity limit 32% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.